{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:42:07Z","timestamp":1791895327215,"version":"4.3.4"},"reference-count":167,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Plan","award":["2017YFA0505901"],"award-info":[{"award-number":["2017YFA0505901"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570007"],"award-info":[{"award-number":["81570007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Abnormally O-glycosylated MUC1 tandem repeat glycopeptide epitopes expressed by multiple types of cancer have long been attractive targets for therapy in the race against genetic mutations of tumor cells. Glycopeptide signature-guided therapy might be a more promising avenue than mutation signature-guided therapy. Three O-glycosylated peptide motifs, PDTR, GSTA, and GVTS, exist in a tandem repeat HGVTSAPDTRPAPGSTAPPA, containing five O-glycosylation sites. The exact peptide and sugar residues involved in antibody binding are poorly defined. Co-crystal structures of glycopeptides and respective monoclonal antibodies are very few. Here we review 3 groups of monoclonal antibodies: antibodies which only bind to peptide portion, antibodies which only bind to sugar portion, and antibodies which bind to both peptide and sugar portions. The antigenicity of peptide and sugar portions of glyco-MUC1 tandem repeat were analyzed according to available biochemical and structural data, especially the GSTA and GVTS motifs independent from the most studied PDTR. Tn is focused as a peptide-modifying residue in vaccine design, to induce glycopeptide-binding antibodies with cross reactivity to Tn-related tumor glycans, but not glycans of healthy cells. The unique requirement for the designs of antibody in antibody-drug conjugate, bi-specific antibodies, and chimeric antigen receptors are also discussed.<\/jats:p>","DOI":"10.3390\/molecules23061326","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T03:02:50Z","timestamp":1527822170000},"page":"1326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1347-3811","authenticated-orcid":false,"given":"Dapeng","family":"Zhou","sequence":"first","affiliation":[{"name":"Shanghai Pulmonary Hospital Affiliated with Tongji University School of Medicine, Shanghai 200092, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Xu","sequence":"additional","affiliation":[{"name":"Laboratory of Antibody Structure, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and iHuman Institute, ShanghaiTech University, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Tonn","sequence":"additional","affiliation":[{"name":"Institute for Transfusion Medicine Dresden, German Red Cross Blood Donation Service North-East, D-01307 Dresden, Germany"},{"name":"Medical Faculty, Carl Gustav Carus Technical University Dresden, D-01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1002\/(SICI)1097-0142(19961215)78:12<2601::AID-CNCR28>3.0.CO;2-Z","article-title":"The early implementation of the National Cancer Act of 1971","volume":"78","author":"Murphy","year":"1996","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1440-1711.2005.01351.x","article-title":"Altered glycosylation of proteins produced by malignant cells, and application for the diagnosis and immunotherapy of tumours","volume":"83","author":"Kobata","year":"2005","journal-title":"Immunol. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1182\/blood.V14.10.1079.1079","article-title":"Acquired hemolytic anemia with polyagglutinability of red blood cells due to a new factor present in normal human serum (Anti-Tn)","volume":"14","author":"Dausset","year":"1959","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1172\/JCI116434","article-title":"Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome","volume":"91","author":"Thurnher","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41523","DOI":"10.1074\/jbc.M112.371989","article-title":"Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing Tn antigen","volume":"287","author":"Mi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.bbagen.2016.03.008","article-title":"Short O-GalNAc glycans: Regulation and role in tumor development and clinical perspectives","volume":"1860","author":"Chia","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/prca.201300024","article-title":"Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers","volume":"7","author":"Ju","year":"2013","journal-title":"Proteom. Clin. Appl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0161-5890(89)90013-8","article-title":"Tn epitope (N-acetyl-d-galactosamine alpha-O-serine\/threonine) density in primary breast carcinoma: A functional predictor of aggressiveness","volume":"26","author":"Springer","year":"1989","journal-title":"Mol. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jb\/mvt052","article-title":"Renewed interest in basic and applied research involving monoclonal antibodies against an oncofetal Tn-antigen","volume":"154","year":"2013","journal-title":"J. Biochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/CBM-130375","article-title":"The Cosmc connection to the Tn antigen in cancer","volume":"14","author":"Ju","year":"2014","journal-title":"Cancer Biomark."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3390\/biom5031783","article-title":"Challenges in Antibody Development against Tn and Sialyl-Tn Antigens","volume":"5","author":"Loureiro","year":"2015","journal-title":"Biomolecules"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1586\/14760584.3.6.655","article-title":"Vaccination with Theratope (STn-KLH) as treatment for breast cancer","volume":"3","author":"Holmberg","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10719-007-9034-3","article-title":"The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression","volume":"24","author":"Yu","year":"2007","journal-title":"Glycoconj. J."},{"key":"ref_14","first-page":"291","article-title":"Glycodendrimers: Novel glycotope isosteres unmasking sugar coding. Case study with T-antigen markers from breast cancer MUC1 glycoprotein","volume":"90","author":"Roy","year":"2002","journal-title":"J. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s001090050144","article-title":"Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy","volume":"75","author":"Springer","year":"1997","journal-title":"J. Mol. Med."},{"key":"ref_16","first-page":"263","article-title":"The Thomsen-Friedenreich (TF) antigen: A critical review on the structural, biosynthetic and histochemical aspects of a pancarcinoma-associated antigen","volume":"12","author":"Hanisch","year":"1997","journal-title":"Histol. Histopathol."},{"key":"ref_17","first-page":"45","article-title":"T-antigens in primary non-invasive and superficially invasive human urinary bladder tumors: The correlation to tumor recurrence and tumor progression. A mini-review","volume":"172","author":"Langkilde","year":"1995","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1016\/j.bmc.2013.02.040","article-title":"One-pot multi-enzyme (OPME) chemoenzymatic synthesis of sialyl-Tn-MUC1 and sialyl-T-MUC1 glycopeptides containing natural or non-natural sialic acid","volume":"21","author":"Malekan","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/pr800710f","article-title":"Comparative studies on the structural features of O-glycans between leukemia and epithelial cell lines","volume":"8","author":"Yamada","year":"2009","journal-title":"J. Proteome Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5099\/aj090100001","article-title":"Analysis of Recombinant CD24 Glycans by MALDI-TOF-MS Reveals Prevalence of Sialyl-T Antigen","volume":"1","author":"Motari","year":"2009","journal-title":"Am. J. Biomed. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00428-007-0478-4","article-title":"Changes in the profile of simple mucin-type O-glycans and polypeptide GalNAc-transferases in human testis and testicular neoplasms are associated with germ cell maturation and tumour differentiation","volume":"451","author":"Poll","year":"2007","journal-title":"Virchows Arch."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2174\/156800906778194577","article-title":"Synthetic glycopeptides from the mucin family as potential tools in cancer immunotherapy","volume":"6","author":"Becker","year":"2006","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.carres.2006.02.017","article-title":"The pattern of glycosyl- and sulfotransferase activities in cancer cell lines: A predictor of individual cancer-associated distinct carbohydrate structures for the structural identification of signature glycans","volume":"341","author":"Chandrasekaran","year":"2006","journal-title":"Carbohydr. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1039\/b514918e","article-title":"More immunogenic Formation of lactones from sialylated MUC1 glycopeptides","volume":"4","author":"Pudelko","year":"2006","journal-title":"Org. Biomol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1002\/chem.200400228","article-title":"Biomimetic synthesis of the tumor-associated (2,3)-sialyl-T antigen and its incorporation into glycopeptide antigens from the mucins MUC1 and MUC4","volume":"10","author":"Dziadek","year":"2004","journal-title":"Chemistry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1053\/gast.1996.v110.pm8613039","article-title":"Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis","volume":"110","author":"Bresalier","year":"1996","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3892\/ijo.2015.3302","article-title":"Molecular basis of antibody binding to mucin glycopeptides in lung cancer","volume":"48","author":"Qu","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/2326-6066.CIR-17-0112","article-title":"Human Tumor Antigens Yesterday, Today, and Tomorrow","volume":"5","author":"Finn","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.3390\/cancers3033073","article-title":"Natural and Induced Humoral Responses to MUC1","volume":"3","author":"Moreno","year":"2011","journal-title":"Cancers"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/glycob\/cwh090","article-title":"Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1)","volume":"14","author":"Karsten","year":"2004","journal-title":"Glycobiology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9833","DOI":"10.1021\/ja020208f","article-title":"Principles of mucin architecture: Structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains","volume":"124","author":"Coltart","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1073\/pnas.1115166109","article-title":"Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine","volume":"109","author":"Lakshminarayanan","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31740","DOI":"10.1038\/srep31740","article-title":"Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential","volume":"6","author":"Lohmueller","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/glycob\/cwj044","article-title":"Chemoenzymatically synthesized multimeric Tn\/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance","volume":"16","author":"Reis","year":"2006","journal-title":"Glycobiology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3892\/ijo.2012.1645","article-title":"MUC1 glycopeptide epitopes predicted by computational glycomics","volume":"41","author":"Song","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.molimm.2015.02.028","article-title":"Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies","volume":"67","author":"Dingjan","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sbi.2016.10.009","article-title":"Antibody recognition of aberrant glycosylation on the surface of cancer cells","volume":"44","author":"Soliman","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_40","first-page":"3118","article-title":"Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3","volume":"46","author":"Thor","year":"1986","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF02484401","article-title":"Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: A systematic and comparative study","volume":"106","author":"Cao","year":"1996","journal-title":"Histochem. Cell Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"10056","DOI":"10.1073\/pnas.0915176107","article-title":"Antibody recognition of a unique tumor-specific glycopeptide antigen","volume":"107","author":"Brooks","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/science.1129200","article-title":"A mutant chaperone converts a wild-type protein into a tumor-specific antigen","volume":"314","author":"Schietinger","year":"2006","journal-title":"Science"},{"key":"ref_44","first-page":"2997","article-title":"The role of podoplanin in tumor progression and metastasis","volume":"28","author":"Raica","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","article-title":"Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization","volume":"15","author":"Klein","year":"2013","journal-title":"Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jb\/mvs007","article-title":"Construction and expression of anti-Tn-antigen-specific single-chain antibody genes from hybridoma producing MLS128 monoclonal antibody","volume":"151","author":"Yuasa","year":"2012","journal-title":"J. Biochem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/hyb.1997.16.317","article-title":"Molecular cloning of a monoclonal anti-tumor antibody specific for the Tn antigen and expression of an active single-chain Fv fragment","volume":"16","author":"Babino","year":"1997","journal-title":"Hybridoma"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000056500","article-title":"Summary report on the ISOBM TD-4 Workshop: Analysis of 56 monoclonal antibodies against the MUC1 mucin","volume":"19","author":"Price","year":"1998","journal-title":"Tumour Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1006\/jmbi.1998.2209","article-title":"Crystal structure at 1.95 A resolution of the breast tumour-specific antibody SM3 complexed with its peptide epitope reveals novel hypervariable loop recognition","volume":"284","author":"Dokurno","year":"1998","journal-title":"J. Mol. Biol."},{"key":"ref_50","first-page":"5476","article-title":"Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin","volume":"47","author":"Burchell","year":"1987","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/ijc.2910430620","article-title":"A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas","volume":"43","author":"Girling","year":"1989","journal-title":"Int. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1046\/j.1432-1033.2002.02787.x","article-title":"NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3","volume":"269","author":"Serttas","year":"2002","journal-title":"Eur. J. Biochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9830","DOI":"10.1002\/anie.201502813","article-title":"Deciphering the Non-Equivalence of Serine and Threonine O-Glycosylation Points: Implications for Molecular Recognition of the Tn Antigen by an anti-MUC1 Antibody","volume":"54","author":"Madariaga","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/bip.22313","article-title":"Mucin-type glycopeptide structure in solution: Past, present, and future","volume":"99","author":"Barchi","year":"2013","journal-title":"Biopolymers"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/glycob\/cwg109","article-title":"Conformational studies on the MUC1 tandem repeat glycopeptides: Implication for the enzymatic O-glycosylation of the mucin protein core","volume":"13","author":"Kinarsky","year":"2003","journal-title":"Glycobiology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1021\/bi3013142","article-title":"Site-specific conformational alteration induced by sialylation of MUC1 tandem repeating glycopeptides at an epitope region for the anti-KL-6 monoclonal antibody","volume":"52","author":"Matsushita","year":"2013","journal-title":"Biochemistry"},{"key":"ref_57","first-page":"91","article-title":"Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen","volume":"61","author":"Schuman","year":"2003","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_58","first-page":"677","article-title":"Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen","volume":"27","author":"Movahedin","year":"2017","journal-title":"Glycobiology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/15368590152740716","article-title":"Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine","volume":"20","author":"Qi","year":"2001","journal-title":"Hybrid. Hybridomics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14712598.2015.993375","article-title":"Glycoconjugate vaccines: An update","volume":"15","author":"Vella","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40265-013-0048-9","article-title":"Meningococcal groups C and Y and haemophilus B tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix\u00ae): A review","volume":"73","author":"Perry","year":"2013","journal-title":"Drugs"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1586\/erv.11.14","article-title":"Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy","volume":"10","author":"Pollard","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7150\/jca.7028","article-title":"Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial","volume":"4","author":"Ibrahim","year":"2013","journal-title":"J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1046\/j.1471-4159.2000.0750404.x","article-title":"High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: Reexamination of GD1a immunolocalization","volume":"75","author":"Lunn","year":"2000","journal-title":"J. Neurochem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/chem.201603921","article-title":"Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures","volume":"23","author":"Pett","year":"2017","journal-title":"Chemistry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/0008-5472.CAN-09-2893","article-title":"Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes","volume":"70","author":"Wandall","year":"2010","journal-title":"Cancer Res."},{"key":"ref_67","first-page":"356","article-title":"Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions","volume":"28","author":"Szpak","year":"1984","journal-title":"Acta Cytol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.4049\/jimmunol.151.11.6559","article-title":"Preferential use of a H chain V region in antitumor-associated glycoprotein-72 monoclonal antibodies","volume":"151","author":"Rixon","year":"1993","journal-title":"J. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/jb\/mvq014","article-title":"Isolation and characterization of antibodies against three consecutive Tn-antigen clusters from a phage library displaying human single-chain variable fragments","volume":"147","author":"Sakai","year":"2010","journal-title":"J. Biochem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0022-1759(02)00298-3","article-title":"The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat","volume":"270","author":"Takeuchi","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00701329","article-title":"Expression of MAM-3 and MAM-6 antigens in endometrial and endocervical adenocarcinomas","volume":"407","author":"Tsubura","year":"1985","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"17102","DOI":"10.1021\/ja903361f","article-title":"An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library","volume":"131","author":"Ohyabu","year":"2009","journal-title":"J. Am. Chem. Soc."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.bbagen.2013.11.009","article-title":"A straightforward protocol for the preparation of high performance microarray displaying synthetic MUC1 glycopeptides","volume":"1840","author":"Matsushita","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.celrep.2017.02.003","article-title":"Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates","volume":"18","author":"Saunders","year":"2017","journal-title":"Cell Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10652","DOI":"10.1002\/anie.201304212","article-title":"Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines","volume":"52","author":"Nuhn","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/adhm.201400460","article-title":"CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines","volume":"4","author":"Hartmann","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1002\/chem.201400256","article-title":"A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer","volume":"20","author":"Glaffig","year":"2014","journal-title":"Chemistry"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1039\/C5OB01255D","article-title":"Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers","volume":"13","author":"Glaffig","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10611860410001670026","article-title":"Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses","volume":"11","author":"Diwan","year":"2003","journal-title":"J. Drug Target"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1021\/js980070s","article-title":"Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses","volume":"87","author":"Newman","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1021\/acschembio.5b00406","article-title":"Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine","volume":"10","author":"Yin","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1021\/cb400060x","article-title":"Boosting immunity to small tumor-associated carbohydrates with bacteriophage q\u03b2 capsids","volume":"8","author":"Yin","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1517\/14712598.2015.1088519","article-title":"Update on Mucin-1 immunotherapy in cancer: A clinical perspective","volume":"15","author":"Rivalland","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Hossain, M.K., and Wall, K.A. (2016). Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines. Vaccines, 4.","DOI":"10.3390\/vaccines4030025"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1158\/2326-6066.CIR-15-0189","article-title":"Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I\/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer","volume":"4","author":"Scheid","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0968-0896(01)00433-3","article-title":"Novel Tn antigen-containing neoglycopeptides: Synthesis and evaluation as anti tumor vaccines","volume":"10","author":"Cipolla","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1039\/c1cc10192g","article-title":"Rational design of a Tn antigen mimic","volume":"47","author":"Corzana","year":"2011","journal-title":"Chem. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1021\/acs.joc.6b00833","article-title":"Design of alpha-S-Neoglycopeptides Derived from MUC1 with a Flexible and Solvent-Exposed Sugar Moiety","volume":"81","author":"Companon","year":"2016","journal-title":"J. Org. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/cbic.201600473","article-title":"A Synthetic MUC1 Glycopeptide Bearing betaGalNAc-Thr as a Tn Antigen Isomer Induces the Production of Antibodies against Tumor Cells","volume":"18","author":"Riul","year":"2017","journal-title":"Chembiochem"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8498","DOI":"10.1002\/anie.201003810","article-title":"Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue","volume":"49","author":"Kaiser","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1021\/bc060103s","article-title":"Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines","volume":"17","author":"Wu","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1021\/bc800243f","article-title":"Synthetic and immunological studies of 5\u2032-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins","volume":"19","author":"Wang","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/ml100313d","article-title":"Synthetic and Immunological Studies of sTn Derivatives Carrying 5-N-(p-Substituted Phenylacetyl)Sialic Acid for the Development of Effective Cancer Vaccines","volume":"2","author":"Wang","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8691","DOI":"10.1039\/c1cc12732b","article-title":"Efficient chemoenzymatic synthesis of sialyl Tn-antigens and derivatives","volume":"47","author":"Ding","year":"2011","journal-title":"Chem. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1039\/C4OB02424A","article-title":"Synthetic and immunological studies of N-acyl modified S-linked STn derivatives as anticancer vaccine candidates","volume":"13","author":"Huo","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/glycob\/cwl061","article-title":"Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat","volume":"17","author":"Tarp","year":"2007","journal-title":"Glycobiology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"6822","DOI":"10.1158\/1078-0432.CCR-11-1151","article-title":"Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer","volume":"17","author":"Ibrahim","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2016.05.003","article-title":"A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas","volume":"63","author":"Fiedler","year":"2016","journal-title":"Eur. J. Cancer."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2005.02.5973","article-title":"Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission","volume":"24","author":"Verheijen","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/JCO.2000.18.2.363","article-title":"Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595","volume":"18","author":"Hughes","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1023\/A:1008349300781","article-title":"Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer","volume":"11","author":"Gillespie","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_102","first-page":"1679","article-title":"Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer","volume":"4","author":"Kramer","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1464-410X.1995.tb07837.x","article-title":"Targeting of bladder cancer with monoclonal antibody NCRC48\u2014A possible approach for intravesical therapy","volume":"76","author":"Kunkler","year":"1995","journal-title":"Br. J. Urol."},{"key":"ref_104","first-page":"1067","article-title":"Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: Phase I study","volume":"34","author":"Kramer","year":"1993","journal-title":"J. Nucl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"20866","DOI":"10.1074\/jbc.M112.357293","article-title":"The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function","volume":"287","author":"Ahmad","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e27317","DOI":"10.4161\/onci.27317","article-title":"Genetic variants of IgG1 antibodies and Fc\u03b3RIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells","volume":"3","author":"Pandey","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10719-012-9437-7","article-title":"Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity","volume":"30","author":"Lavrsen","year":"2013","journal-title":"Glycoconj. J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Miles","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1200\/JCO.2015.62.6846","article-title":"CD33 Expression and Its Association with Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children\u2019s Oncology Group Trial AAML0531","volume":"34","author":"Pollard","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2016.34.15_suppl.2511","article-title":"A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870)","volume":"34","author":"Boni","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/19420862.2017.1290752","article-title":"Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity","volume":"9","author":"Prendergast","year":"2017","journal-title":"MAbs"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1677\/erc.1.00766","article-title":"Identification and validation of cell surface antigens for antibody targeting in oncology","volume":"11","author":"Carter","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: Introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/cpt.651","article-title":"Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment","volume":"101","author":"Yuraszeck","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00262-006-0135-9","article-title":"PankoMab: A potent new generation anti-tumour MUC1 antibody","volume":"55","author":"Danielczyk","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.immuni.2016.10.015","article-title":"Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety","volume":"45","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Steentoft, C., Migliorini, D., King, T.R., Mandel, U., June, C.H., and Posey, A.D. (2018). Glycan-directed CAR-t cells. Glycobiology.","DOI":"10.1093\/glycob\/cwy008"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.immuni.2016.10.014","article-title":"Targeting of Tumor-Associated Glycoforms of MUC1 with CAR T Cells","volume":"45","author":"Maher","year":"2016","journal-title":"Immunity"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/pcan.2012.49","article-title":"Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer","volume":"16","author":"Sanchez","year":"2013","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s13238-017-0422-6","article-title":"Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation","volume":"8","author":"Liu","year":"2017","journal-title":"Protein Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jcmm.12810","article-title":"CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies","volume":"20","author":"Romanski","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"ref_131","first-page":"djv375","article-title":"ErbB2\/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma","volume":"108","author":"Zhang","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: An \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.trsl.2017.06.003","article-title":"Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy","volume":"187","author":"Bollino","year":"2017","journal-title":"Transl. Res."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Du, S.H., Li, Z., Chen, C., Tan, W.K., Chi, Z., Kwang, T.W., Xu, X.H., and Wang, S. (2016). Co-Expansion of Cytokine-Induced Killer Cells and V\u03b39V\u03b42 T Cells for CAR T-Cell Therapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0161820"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1172\/JCI83476","article-title":"CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo","volume":"126","author":"Tian","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nbt.2492","article-title":"High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire","volume":"31","author":"DeKosky","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.187.1.59","article-title":"Somatic hypermutation introduces insertions and deletions into immunoglobulin V genes","volume":"187","author":"Wilson","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1073\/pnas.86.17.6709","article-title":"A repertoire of monoclonal antibodies with human heavy chains from transgenic mice","volume":"86","author":"Caskey","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/368856a0","article-title":"Antigen-specific human antibodies from mice comprising four distinct genetic modifications","volume":"368","author":"Lonberg","year":"1994","journal-title":"Nature"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.4049\/jimmunol.163.12.6898","article-title":"Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and \u03ba and \u03bb light chain yeast artificial chromosomes","volume":"163","author":"Nicholson","year":"1999","journal-title":"J. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.4049\/jimmunol.1203041","article-title":"High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH\/Ig\u03ba\/Ig\u03bb loci bearing the rat CH region","volume":"190","author":"Osborn","year":"2013","journal-title":"J. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00005-014-0322-x","article-title":"Human antibody production in transgenic animals","volume":"63","author":"Osborn","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-04-709584","article-title":"A novel humanized mouse model with significant improvement of class-switched, antigen-specific antibody production","volume":"129","author":"Yu","year":"2017","journal-title":"Blood"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1002\/pmic.200800793","article-title":"Proteomics of MUC1-containing lipid rafts from plasma membranes and exosomes of human breast carcinoma cells MCF-7","volume":"9","author":"Staubach","year":"2009","journal-title":"Proteomics"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"63265","DOI":"10.18632\/oncotarget.18792","article-title":"Chemotherapy administration to breast cancer patients affects extracellular vesicles thrombogenicity and function","volume":"8","author":"Aharon","year":"2017","journal-title":"Oncotarget"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbrc.2018.03.107","article-title":"Detection and proteomic characterization of extracellular vesicles in human pancreatic juice","volume":"499","author":"Osteikoetxea","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1039\/B916199F","article-title":"Microfluidic isolation and transcriptome analysis of serum microvesicles","volume":"10","author":"Chen","year":"2010","journal-title":"Lab Chip"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1039\/C4LC00136B","article-title":"Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes","volume":"14","author":"Kanwar","year":"2014","journal-title":"Lab Chip"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"014112","DOI":"10.1063\/1.4907807","article-title":"Rapid inertial solution exchange for enrichment and flow cytometric detection of microvesicles","volume":"9","author":"Dudani","year":"2015","journal-title":"Biomicrofluidics"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1039\/C5AN01648G","article-title":"Microfluidic compartments with sensing microbeads for dynamic monitoring of cytokine and exosome release from single cells","volume":"141","author":"Son","year":"2016","journal-title":"Analyst"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"13495","DOI":"10.1039\/C7NR04557C","article-title":"High-purity capture and release of circulating exosomes using an exosome-specific dual-patterned immunofiltration (ExoDIF) device","volume":"9","author":"Kang","year":"2017","journal-title":"Nanoscale"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2013.10.008","article-title":"EarlyCDT(R)-lung, in 1600 patients: An evaluation of its performance in routine clinical practice","volume":"83","author":"Jett","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e1384108","DOI":"10.1080\/2162402X.2017.1384108","article-title":"Early detection of lung cancer by using an autoantibody panel in Chinese population","volume":"7","author":"Ren","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1749-6632.1993.tb44012.x","article-title":"Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA","volume":"690","author":"Domenech","year":"1993","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0022-2836(02)00196-1","article-title":"Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: A new approach for vaccine design","volume":"318","author":"Apostolopoulos","year":"2002","journal-title":"J. Mol. Biol."},{"key":"ref_157","first-page":"D1311","article-title":"Getting into the groove: Unusual features of peptide binding to MHC class I molecules and implications in vaccine design","volume":"6","author":"Apostolopoulos","year":"2001","journal-title":"Front. Biosci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.4049\/jimmunol.166.11.6555","article-title":"Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection","volume":"166","author":"Soares","year":"2001","journal-title":"J. Immunol."},{"key":"ref_159","first-page":"848s","article-title":"MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo","volume":"7","author":"Mukherjee","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.intimp.2004.10.004","article-title":"T cells recognize PD(N\/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1","volume":"5","author":"Pisarev","year":"2005","journal-title":"Int. Immunopharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3233\/BD-2004-20107","article-title":"Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model","volume":"20","author":"Mukherjee","year":"2004","journal-title":"Breast Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.1158\/1078-0432.CCR-05-1330","article-title":"Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells","volume":"11","author":"Koido","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2249.2005.02965.x","article-title":"O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma","volume":"143","author":"Stepensky","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2008.09.032","article-title":"Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes","volume":"47","author":"Ninkovica","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1515\/BC.2009.070","article-title":"Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice","volume":"390","author":"Ryan","year":"2009","journal-title":"Biol. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"8730","DOI":"10.1021\/ja211725s","article-title":"A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy","volume":"134","author":"Huang","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/cbic.201402077","article-title":"Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist","volume":"15","author":"Lakshminarayanan","year":"2014","journal-title":"Chembiochem"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/6\/1326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:06:42Z","timestamp":1760195202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/6\/1326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":167,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["molecules23061326"],"URL":"https:\/\/doi.org\/10.3390\/molecules23061326","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]}}}